Stay updated with breaking news from Boxer Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tango Therapeutics (NASDAQ:TNGX – Free Report) had its price target lowered by Guggenheim from $16.00 to $14.00 in a report published on Friday, Benzinga reports. The firm currently has a buy rating on the stock. Several other research analysts have also issued reports on TNGX. Barclays lowered their target price on Tango Therapeutics from $18.00 […]
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash...
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!